Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07537335

Knee Osteoartritis Genicular Nerve RF Ablation vs Alcohol Neurolysis

The GEN-AL-RF study is a randomized controlled trial designed to compare the clinical efficacy of two interventional techniques for managing chronic knee pain due to osteoarthritis. The study focuses on genicular nerve radiofrequency (RF) ablation versus neurolytic alcohol injection for pain blockade.

Patients diagnosed with knee osteoarthritis are randomly assigned to either the RF ablation group or the neurolytic alcohol group. The primary objective is to evaluate the superiority and duration of analgesic effects between these two methods. Clinical outcomes are assessed at baseline and at 1, 3, and 6 months post-procedure using the Numeric Rating Scale (NRS) for pain intensity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) for physical function, and the Short Form-12 (SF-12) for health-related quality of life.

The results of this study aim to provide high-quality evidence regarding the comparative effectiveness and long-term outcomes of genicular nerve RF and alcohol neurolysis in the clinical management of chronic knee osteoarthritis pain.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Knee Osteoarthristis NEUROLYSIS Radiofrequency Ablation

Age range

45 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The GEN-AL-RF study investigates the clinical outcomes of two ultrasound-guided genicular nerve procedures in patients with Grade 3-4 knee osteoarthritis according to Kellgren-Lawrence criteria. Patients who have failed conservative treatment options are enrolled and randomly assigned to one of two intervention groups.

Under real-time ultrasound guidance, the superior medial, superior lateral, and inferior medial genicular nerves are targeted. In the Thermal Radiofrequency (RF) group, patients receive RF ablation at 75°C for 90 seconds per target nerve. In the Neurolytic Alcohol group, 1 mL of absolute ethanol is injected at each of the three anatomical targets. Both procedures are performed by experienced physicians using standardized needle placement techniques.

Clinical assessments are conducted at baseline and at follow-up intervals of 1, 3, and 6 months. The primary outcome is pain intensity measured by the Numeric Rating Scale (NRS). Secondary outcomes include physical function measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and health-related quality of life measured by the Short Form-12 (SF-12) survey. Safety is monitored throughout the study period by documenting any procedure-related adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: Patients aged 45 to 85 years.
  • Diagnosis: Chronic knee pain for at least 6 months diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) criteria.
  • Radiological Grade: Grade 3 or 4 according to the Kellgren-Lawrence (K-L) classification.
  • Pain Severity: Baseline Numerical Rating Scale (NRS) score of 5 or higher.
  • Failure of Conservative Treatment: Inadequate response to conservative treatments (e.g., physical therapy, NSAIDs, or intra-articular injections) for at least 3 months.
  • Positive Diagnostic Block: At least 50% reduction in pain for minimum 24 hours following a prognostic genicular nerve block with local anesthetic.

Exclusion criteria

  • Previous Surgery: History of knee arthroplasty or major knee surgery on the affected side.
  • Specific Conditions: Presence of inflammatory arthritis (e.g., rheumatoid arthritis), gouty arthritis, or active infection at the injection site.
  • Neurological Deficit: Severe neurological or psychiatric disorders that may interfere with pain assessment.
  • Coagulopathy: Uncontrolled bleeding disorders or use of anticoagulant therapy that cannot be temporarily discontinued.
  • Recent Injections: Intra-articular steroid or hyaluronic acid injection within the last 3 months.
  • Allergy: Known allergy to local anesthetics, contrast agents, or ethyl alcohol.
  • Pacemaker: Presence of a cardiac pacemaker or implanted electronic device (specifically for the RFA group).

Treatment and study plan

Genicular nerve block

Other

Genicular nerve radiofrequency ablation : Patients will undergo ultrasound or fluoroscopy-guided radiofrequency ablation of the genicular nerves (superior medial, superior lateral, and inferior medial). The procedure involves placing RF cannulas at the target neural sites. Once the position is confirmed by sensory and motor stimulation, thermal radiofrequency lesioning will be performed to disrupt pain signal transmission.

Genicular nerve chemichal neurolysis: Patients will receive ultrasound or fluoroscopy-guided chemical neurolysis of the genicular nerves (superior medial, superior lateral, and inferior medial). Following correct needle placement confirmed by contrast spread or local anesthetic test block, a specific volume (1 mL per nerve) of ethyl alcohol (95-96% concentration) will be injected to achieve long-term neurolytic blockade of the target nerves.

Other names: genicular nerve chemical neurolysis, genicular nerve radiofrequency ablation

Primary outcomes

  1. Change from Baseline in Numeric Rating Scale (NRS) Score at 6 Months.

    Time frame: 1 month, 3 months, and 6 months.

    The Numeric Rating Scale (NRS) is a segmented numerical version of the visual analog scale in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain. The score ranges from 0 (no pain) to 10 (worst possible pain). A decrease in score indicates pain relief.

Secondary outcomes

  1. Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score

    Time frame: 1 month, 3 months, and 6 months post-procedure.

    The WOMAC is a proprietary set of standardized questionnaires used to evaluate the condition of patients with osteoarthritis of the knee and hip, including segments for pain, stiffness, and physical function. Higher scores indicate worse outcomes.

  2. Change from Baseline in 12-Item Short Form Health Survey (SF-12) Score.

    Time frame: 1 month, 3 months, and 6 months post-procedure

    The SF-12 is a self-reported outcome measure assessing health-related quality of life. It yields two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Higher scores indicate better physical and mental health.

Study contacts

Contact information is provided by the study sponsor or research team.

murat erten

CONTACT

[email protected]

+905435118202

Sponsors and collaborators

Lead sponsor

Sakarya University

Other

Registry information

Official study title

Comparison of Genicular Nerve Radiofrequency Ablation and Neurolytic Alcohol Injection for Chronic Knee Osteoarthritis Pain: A Randomized Controlled Trial

Acronym: GEN-AL-RF

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 17, 2026
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.